Another two biopharma companies priced IPOs on Nasdaq to raise a combined $350 million, becoming the fourth and fifth firms to debut on U.S. markets in 2026.

After keeping the faith when it failed in the Modify phase III trial in October 2021, Idorsia Ltd. now has a clear route to market for lucerastat, an oral therapy for Fabry disease.

These graphs compare the performance of the biotech stocks for all of 2025 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.

Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Biocomposites, Eyas, Insightec, Mirum, Sonorous Neurovascular.

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Apotex, Chemometec, Eisai, Grünenthal, Henlius, Endomimetics, Everest, Factor, Imunon, Liger, Micot, Phase Scientific, Roche, Searchlight, Tempest, Watchmaker, Visby, Vectus, Xortx.

Clinical updates for biopharma and med tech, including data readouts and publications: Aicuris, Alvotech, Ayrmid, Exicure, Pentixapharm.

Biopharma and med-tech companies raising money in public or private financings, including: Angitia, Collplant, GE Medical Holding, Generate, Exact, Inspira, LB, Myndtec.